Security Snapshot

ISHARES INC - US INTL HGH YLD (GHYG) Institutional Ownership

CUSIP: 464286178

13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

46

Shares (Excl. Options)

3,140,223

Price

$46.13

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Type / Class
Equity / US INTL HGH YLD
Symbol
GHYG
Price per share
$45.60
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
3,140,223
Total reported value
$144,882,335
% of total 13F portfolios
0%
Share change
+173,533
Value change
+$8,005,178
Number of holders
46
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • GHYG - ISHARES INC - US INTL HGH YLD is tracked under CUSIP 464286178.
  • 46 institutions reported positions in Q4 2025.
  • Schedule 13D/13G significant owner rows are not currently available.

What Changed

  • Holder count moved from 46 to 34 between Q4 2025 and Q1 2026.
  • Reported value moved from $144,882,335 to $67,097,058.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 46 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 464286178?
CUSIP 464286178 identifies GHYG - ISHARES INC - US INTL HGH YLD in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

As of 31 Dec 2025, 46 institutional investors reported holding 3,140,223 shares of ISHARES INC - US INTL HGH YLD (GHYG).

Institutional Holders of ISHARES INC - US INTL HGH YLD (GHYG) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 1,491,393 $67,097,058 +$4,611,272 $45.11 34
2025 Q4 3,140,223 $144,882,335 +$8,005,178 $46.13 46
2025 Q3 2,906,844 $135,265,462 +$9,480,164 $46.54 42
2025 Q2 2,695,324 $124,832,518 -$9,425,194 $46.31 45
2025 Q1 2,901,978 $129,322,314 +$22,416,069 $44.56 47
2024 Q4 2,403,608 $105,954,611 -$1,217,652 $44.07 45
2024 Q3 2,342,529 $107,212,150 +$2,745,212 $45.78 50
2024 Q2 2,285,814 $99,925,370 +$8,554,778 $43.71 49
2024 Q1 2,078,362 $91,747,439 -$220,429 $44.15 48
2023 Q4 1,892,561 $83,704,155 -$16,001,160 $44.23 45
2023 Q3 2,254,584 $93,617,744 +$9,770,146 $41.51 47
2023 Q2 1,928,831 $81,928,238 -$10,733,580 $42.48 44
2023 Q1 2,181,200 $93,383,988 +$31,929,354 $42.82 39
2022 Q4 1,435,646 $59,434,797 -$9,267,045 $41.40 30
2022 Q3 1,768,346 $68,807,418 +$20,559,732 $38.92 28
2022 Q2 1,241,824 $50,453,126 -$14,387,337 $40.63 31
2022 Q1 1,562,067 $74,262,232 -$24,192,990 $46.16 33
2021 Q4 2,193,213 $108,176,710 -$11,746,076 $49.29 37
2021 Q3 2,211,564 $110,705,984 +$3,353,853 $50.05 37
2021 Q2 2,144,519 $109,090,436 +$8,075,107 $50.86 38
2021 Q1 1,987,473 $99,769,898 +$7,766,038 $50.19 38
2020 Q4 1,832,321 $92,946,488 +$7,271,691 $50.73 35
2020 Q3 1,688,954 $81,101,299 +$11,445,864 $48.02 32
2020 Q2 1,457,339 $67,387,852 -$5,336,332 $46.27 33
2020 Q1 1,588,295 $67,138,000 -$10,682,886 $42.28 34
2019 Q4 1,736,474 $86,524,000 -$4,341,025 $49.83 43
2019 Q3 1,822,934 $88,930,428 -$1,146,150 $48.79 41
2019 Q2 1,847,185 $91,073,000 +$15,087,608 $49.33 39
2019 Q1 1,528,017 $74,643,000 -$16,815,645 $48.83 42
2018 Q4 1,866,543 $85,937,000 -$27,812,359 $46.03 43
2018 Q3 2,430,963 $120,395,000 +$12,294,756 $49.53 45
2018 Q2 2,182,827 $106,934,000 +$3,846,456 $48.99 48
2018 Q1 2,100,070 $105,286,000 +$14,869,968 $50.12 50
2017 Q4 1,802,515 $90,942,000 -$8,709,754 $50.45 42
2017 Q3 1,897,861 $97,585,000 +$20,081,825 $51.42 33
2017 Q2 1,553,641 $78,445,000 -$3,339,190 $50.49 34
2017 Q1 1,620,045 $79,952,000 +$39,887,125 $49.36 31
2016 Q4 814,365 $39,481,000 -$7,821,623 $48.48 29
2016 Q3 972,093 $48,098,000 -$10,365,709 $49.49 26
2016 Q2 1,202,199 $57,233,000 +$4,988,122 $47.61 30
2016 Q1 1,092,491 $50,449,000 -$4,753,338 $46.18 21
2015 Q4 1,197,390 $53,489,918 +$5,146,411 $44.62 28
2015 Q3 1,083,109 $50,592,000 +$18,301,616 $46.72 20
2015 Q2 884,217 $43,804,278 -$847,390 $49.54 25
2015 Q1 901,345 $44,564,680 +$8,043,627 $49.45 23
2014 Q4 740,382 $36,823,306 +$34,624,306 $49.73 26
2014 Q3 240 $12,000 -$1,137,000 $50.00 1
2014 Q2 20,935 $1,149,000 $54.90 2
2014 Q1 20,935 $1,138,000 +$186,000 $54.39 2
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .